Myristoylated alanine-rich C-kinase substrate (MARCKS) (MARCKS)

Myristoylated alanine-rich C-kinase substrate (MARCKS) is a ubiquitous intracellular protein that serves as a major substrate for protein kinase C (PKC) and plays a pivotal role in regulating the actin cytoskeleton and signal transduction [1, 5]. The phosphorylation site domain (PSD), also known as the effector domain, is a central, highly basic region of the protein that mediates its attachment to the plasma membrane through electrostatic interactions with acidic phospholipids like PIP2 [1, 3]. Upon phosphorylation by PKC or binding to calcium/calmodulin, the PSD loses its affinity for the membrane, causing MARCKS to translocate to the cytosol—a process essential for triggering cellular events such as airway mucus secretion and cell migration [2, 5]. In pathological states, MARCKS is heavily involved in the mucus hypersecretion seen in chronic obstructive pulmonary disease (COPD) and asthma, as well as in the invasive and metastatic behavior of various cancers [2, 4]. Therapeutic interventions, such as the peptide BIO-11006, specifically target the PSD to inhibit these processes, making it a significant focal point for drug development in respiratory medicine and oncology [2, 3].

Other names

MARCKS effector domainPhosphorylation site domainPSD80K-L proteinMACSPRKCSL

Peptide mimetics target the MARCKS phosphorylation site domain to competitively inhibit its interaction with the plasma membrane and other binding partners, effectively blocking the translocation required for mucus exocytosis and cell migration [2, 3, 5].